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IMMUNE RECONSTITUTION
Chao, N.J. Department of Medicine and Immunology, Division of Cel-
lular Therapy/BMT, Duke University, Durham, NC
An important milestone following allogeneic stem cell transplan-
tation is the full recovery of immune function. Recovery of immu-
nity involves reconstitution of the innate as well as the adaptive
immune cells and their respective function. The most extensively
studied component is the lymphocyte compartment. T-cell recon-
stitution early on following cord blood transplantation involves
expansion of the initial cord blood T cells infused with the stem
cells. This ﬁrst wave of T cells are a result of peripheral expansion
in secondary lymphoid organs. Following peripheral expansion,
there is a slower second wave of donor-derived precursors that
come from the engrafted donor cells. These cells trafﬁc through
the thymus and are educated there. T-cell receptor excision circles
(sjTRECs) are generated within the thymus and identify new
thymic emigrants and those that have not divided. Measurements
of TRECs, spectratyping of the T cell receptor Vbeta families and
extensive phenotypic analyses have allowed us to determine the
time course of T cell reconstitution and some of the factors which
contribute or detract from rapid recovery. sjTRECs were detected
at normal levels in all children starting 12 months after transplant.
sjTRECs were not detected until 18 months after transplant in
adults and then only at a three-fold lower level than expected for
age. T-cell repertoires were skewed in adults and children between
12 and 18 months after transplant, but recovered to near-normal
diversity at between 2 and 3 years. T-cell repertoires appeared
more diverse earlier in children (at 1-2 years) than in adults (at 3-4
years). Thus, T-cell recovery after UCB transplant occurs primar-
ily through peripheral expansion of adoptively transferred donor
T-cells and results in skewing of the T-cell repertoire. The re-
appearance of sjTREC containing cells after UCB transplant is
associated with increasing numbers of phenotypically naïve T-cells,
improved mitogen and recall antigen responses and diversiﬁcation
of the T-cell repertoire. The delay in central T-cell recovery in
adults relative to children may be due to differences in thymic
function resulting from age-related atrophy, graft-versus-host dis-
ease (GVHD) or the pharmacologic effects of prophylaxis and
treatment of GVHD.
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REGULATORY T-CELLS AND CORD BLOOD
Blazar, B.R. University of Minnesota Cancer Center and Department of
Pediatrics, Division of BMT
A subpopulation of naïve CD4 T cells that co-expresses CD25,
the IL-2R alpha chain, has been shown to have potent suppressor
activity. The frequencies of CD4CD25bright cells are higher in
rodents than in humans (8-12% vs 1-3%, respectively, of CD4 T
cells). CD4CD25 cells have been shown to play a vital role in
the induction and maintenance of peripheral self-tolerance and
prevention of systemic autoimmune disorders, including autoim-
mune gastritis, intestinal inﬂammation, and autoimmune diabetes
in diabetes-prone (non-obese diabetes: NOD) mice. Sakaguchi
found that nude mice rejected allogeneic skin grafts faster if trans-
ferred lymphocytes were ﬁrst depleted of CD25 cells indicating
that CD25 cells suppress alloresponses. We have shown that
CD4CD25 regulate T cell alloresponses and tolerance induc-
tion. Depletion of CD425 cells augments a mixed lymphocyte
reaction (MLR) culture whereas adding a graded number of
CD4CD25 T cells resulted in a dose-response reduction in
alloproliferation. Costimulatory pathway blockade can induce tol-
erance to alloantigens in MLR cultures; depletion of CD425
cells from the responder population precludes tolerance induction,
while addback of cells restores tolerance induction revealing an
important role for CD425 cells in this form of tolerance in-
duction. Several laboratories including ours have shown that
CD425T cells present in the donor spleen graft downregulates
graft-versus-host disease (GVHD) lethality while CD4CD25
cells depletion from the donor graft prior to in vivo infusion
resulted in accelerated GVHD morbidity and increased mortality
indicating that CD4CD25 cells play a role in regulation of
GVHD. Supplementation of the donor graft with donor but not
host CD425 cells had a marked amelioration of GVHD lethal-
ity in multiple strain combinations. CD4CD25 cells became
more potent suppressor cells after activation and expansion with
anti-CD3 mAb and IL-2. Therefore, it is not surprising that ex
vivo activation and expansion of CD425 cells by exposure to
reagents that induce TCR ligation and in the presence of a high
concentration of IL-2 resulted in signiﬁcant expansion of this cell
population and increased their anti-GVHD potency. Expansion of
CD425 cells could be achieved by exposure to anti-CD3 mAb
or alloantigen-bearing antigen-presenting cells in the presence of
IL-2. Elucidation of other mechanisms by which activated CD25
cells inhibit GVHD remains unclear. The literature suggests sev-
eral possibilities that are not necessarily mutually exclusive. In vitro
suppression is dependent upon cell-cell contact. Data from Naka-
mura et al suggested that cell surface-bound TGF	 was responsible
for the cell contact-dependent suppression, in contrast to data from
Shevach and colleagues. Thornton and Shevach showed that
CD4CD25 T cells block IL-2 production by the
CD4CD25
 cells at the RNA transcription level. The relative
IL-2 paucity could inhibit the activation, proliferation and effector
function of both CD4CD25
 and CD8 T cells. Other data
indicate that CD152, glucocorticoid-induced TNF receptor
(GITR), or the transcription factor, FoxP3, in CD4CD25 cells
or the activation of CD4CD25 cells by signaling of toll-like
receptors each play an important role in their regulatory function.
Of clinical signiﬁcance, three groups have shown that CD425
cells do not inhibit a GVL effect. Edinger et. al. demonstrated that
cytolytic T cell mediated killing of two different B cell leukemia/
lymphoma cell lines was preserved despite inhibition of GVHD
lethality by CD425 cell infusion. Jones et al showed that
CD8 T cell mediated GVHD was inhibited without precluding
elimination of acute myeloid leukemia cells if CD425 cells
were administered 10 days post-BMT. Trenado et al demonstrated
that ex vivo expanded CD425 cells controlled GVHD but did
not inhibit elimination of a B cell leukemia/lymphoma cell line in
contrast to the graft-versus-tumor (GVT) response to a mastocy-
toma cell line which was impaired. Collectively, these preclinical
data indicate that Tregs inhibit GVHD with the retention of
GVL/GVT in many instances. CD425 T cells are heteroge-
neous in their expression of cell surface antigens. For example,
about 2/3 of CD425 T cells express high levels of the lymph
node (LN) homing receptor, L-selectin (CD62L). Although both
L-Selhi and L-Sello CD425 subsets have in vitro suppressor
function, LSelhi Tregs could have superior therapeutic beneﬁt due
to inhibition of critical early GVHD priming events because of
their ability to home to peripheral LNs via the binding of the L-Sel
molecule to determinants on high endothelial venules in these
LNs. Initial homing of L-Selhi Tregs to the LNs would optimize
the likelihood of interfering with the priming and expansion of
effector T cells thereby inhibiting an early phase of GVHD. Using
whole body imaging, we have demonstrated that LSelhi CD425
cells reduced numbers of green ﬂuorescent protein (GFP) effec-
tor T cells in many types of tissues besides lymphoid organs.
Despite the presumed ability of LSello CD425 cells to migrate
directly to sites of inﬂammation, imaging data indicate little de-
monstrable effect on the accumulation of GFP T cells in GVHD
target organs in LSello-treated mice. In other studies, Ermann et al
conﬁrmed these ﬁndings and reported that only the L-Selhi subset
of CD425 T cells prevented severe tissue damage to the colon
and protected recipients from lethal acute GVHD and concluded
that the ability of Treg cells to efﬁciently enter the priming sites of
pathogenic allo-reactive T cells appears to be a prerequisite for
their protective function in acute GVHD. Thus, optimization of
the homing and migration patterns of CD425 cells may be
critical in achieving the most potent anti-GVHD effects. Since
CD4CD25 cells are capable of suppressing both CD4 and
CD8T cells, it is reasonable to presume that CD4CD25 cells
may be beneﬁcial in suppressing host anti-donor responses that can
cause BM graft rejection. This has now been demonstrated by 3
separate groups using distinct model systems. Joffre et al showed
that preactivated CD425 cells prevented allogeneic BM graft
rejection by host splenocytes given to lethally irradiated recipients.
We have shown that L-selhi but not L-sello preactivated and ex-
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panded CD425 cells prevent BM graft rejection in sublethally
irradiated recipients via a TGF	-independent mechanism. Hanash
and Levy have shown that the addition of donor CD425 cells
resulted in greater lineage committed and multi-potential donor
progenitors in recipient spleens one week post-transplant and sig-
niﬁcantly increased long-term multi-lineage donor chimerism in
sublethally irradiated recipients. A major limitation for the clinical
application of human CD4CD25 cells has been their paucity in
peripheral blood. Only the CD425bright cells are potent sup-
pressors and such cells typically are hypoproliferative. Although
exogenous IL-2 can support human CD4CD25 cell prolifera-
tion the initial protocols published for human CD4CD25 T
cells resulted in limited expansion. However, recent publications
have solved this problem. Studies by Godfrey et al have used a
non-cell sorter, bead-based approach to isolate CD425hi cells
from adult peripheral blood mononuclear cells that were able to be
expanded 100-fold in 2-3 weeks. These expanded CD425
cells were far more potent suppressors of MLR cultures than fresh
cells and retained the expression of L-selhi and other LN homing
receptors. Hoffmann et al have shown that CD425bright cells
can be isolated using cell sorting approaches and that such isolated
cells can be expanded in great numbers while still retaining expres-
sion of L-selhi. Recent studies by Godfrey et al have shown that
cord blood cell CD425 cells are more readily isolated and more
often lead to high levels of suppression as compared to adult
peripheral blood mononuclear cells. These preliminary ﬁndings
demonstrating a high degree of MLR suppression now have been
extended in subsequent studies using 100 cord blood lines gen-
erated to date (B. Blazar and S. Porter, unpublished data). Thus,
the stage is set for clinical trials of CD425 cells for GVHD
inhibition and therapy and engraftment promotion.
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TRANSPLANTATION OF EX VIVO EXPANDED CORD BLOOD
Shpall, E.J.1, de Lima, M.1, McMannis, J.D.1, Robinson, S.1, McNiece,
I.K.2, Champlin, R.E.1 1. The M.D. Anderson Bone Marrow Trans-
plant Department, Houston, TX; 2. Johns Hopkins Oncology Center,
Baltimore, MD
Umbilical cord blood (CB) from unrelated donors is increasingly
used to restore hematopoiesis after myeloablative or more recently,
nonmyeloablative therapy. CB transplants are associated with
higher rates of delayed and failed engraftment than are bone
marrow transplants, particularly for adult patients. At the Univer-
sity of Colorado, we studied the ex vivo expansion of CB in an
attempt to improve time to engraftment and reduce the graft
failure rate in the recipients. In the study, 43 patients with hema-
tologic malignancies (n  40) or breast cancer (n  3) received
high-dose therapy followed by unrelated allogeneic CB transplan-
tation. A fraction of each patient’s CB allograft was CD34-selected
and cultured ex vivo for 10 or 14 days prior to transplantation in
deﬁned media with stem cell factor (SCF), granulocyte colony-
stimulating factor (G-CSF), and megakaryocyte growth and dif-
ferentiation factor (MGDF). The remainder of the CB graft was
infused without further manipulation. Two sequential cohorts of
patients were accrued to the study. The ﬁrst cohort had 40% and
the second cohort had 60% of their CB graft expanded. This study
demonstrated that the CD34 selection and ex vivo expansion of CB
prior to transplantation is feasible. The engraftment failure rate
was relatively low, and the time to neutrophil engraftment in large
adults was in the range reported for pediatric recipients of much
larger CB cell doses. In the successor cord expansion trial being
conducted at the MD Anderson Cancer Center, several changes in
the approach have been made. Patients with hematologic malig-
nancies are now being randomized to receive either two unma-
nipulated CB units or one unmanipulated unit and one unit from
which all the cells are expanded ex vivo. For the patients random-
ized to expansion, on day 
14 one of their cord units is CD133-
selected using the CliniMACS device. The CD133-negative frac-
tion containing the T cells is frozen and the CD133 fraction is
cultured ex vivo for 14 days in media containing SCF, G-CSF and
thrombopoietin (TPO). Following administration of the prepara-
tive regimen, on Day 0, the second unmanipulated CB unit is
infused, followed by the thawed CD133-negative fraction and
ﬁnally, the fraction which has been in culture for two weeks. This
trial was recently initiated and accrual is in progress. Another
expansion trial technology involves the use of a copper chelating
agent, which has been shown by Peled et al to enhance the expan-
sion of a more primitive CD34 CB population when combined
with early acting growth factors. A clinical trial employing this
technology is in progress at MD Anderson. Patients with hemato-
logic malignancies undergoing CB transplantation, with a unit that
is cryopreserved in two fractions are eligible for the study. Twenty
one days prior to infusion, the CD133 cells are isolated from the
smaller cord fraction using the CliniMACS device and cultured for
three weeks in media containing interleukin-6 TPO, FLT-3, SCF,
and the copper chelator tetraethylenepentamine (TEPA). The pa-
tients then receive high-dose therapy with the infusion of the
larger, unmanipulated CB fraction on day 0, and infusion of the
smaller expanded fraction of day 1. Thus far 10 patients have
been enrolled on the study. Evaluable patients engrafted neutro-
phils a median of 27 (range 16-46) in and platelets in a median of
52 (range 27-105) days. An alternative approach for ex vivo expan-
sion is the co-culture of CB cells with bone marrow mesenchymal
stem cells (MSCs) which provide a microenvironment for the
complex molecular cues that direct self-renewal/proliferation and
regulate the differentiation and maturation of hematopoietic prog-
eny. McNiece et al have reported impressive expansion of CB on
MSC stroma. Robinson et al have shown superior expansion of CB
in MSC co-cultures when compared to liquid cultures of the same
CD133 CB fractions. Infusion of MSCs has been shown to
promote engraftment of human CD34 cells in NOD/SCID mice
and fetal sheep. Importantly MSC have been shown to have im-
munomodulatory activity which may reduce graft versus host dis-
ease and enhance engraftment in patients. Clinical evaluation of
CB expansion on MSCs is planned. The pre-clinical data support-
ing this approach as well as updates on the two clinical CB expan-
sion trials described above will be presented at the Los Angeles
meeting.
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IN VIVO STEM CELL FACTOR (R-METHUSCF) AND FILGRASTIM ADMIN-
ISTRATION AFTER UNRELATED UCB TRANSPLANTATION IN ADULTS
Laughlin, M.J. Department of Medicine and Pathology, Case Western
Reserve University, School of Medicine, Cleveland, OH
Allogeneic transplantation with HLA-mismatched unrelated
Umbilical Cord Blood (UCB) is marked by delayed hematologic
recovery when compared with conventional allogeneic graft
sources. UCB graft cell dose correlates with time to myeloid
recovery. Clinical studies have been conducted to improve UCB
graft cell dose including short-term ex vivo expansion, or infusion
of more than one UCB graft. This report summarizes transplant
outcomes for two adults with chronic myelogenous leukemia
(CML), who received myeloablative conditioning followed by in-
fusion of a non-expanded single UCB graft containing a low
mononuclear cell dose. These CML patients were enrolled in a
supportive care clinical transplant trial incorporating in vivo ad-
ministration of recombinant human stem cell factor (R-
MetHuSCF) and ﬁlgrastim administered concomitantly from day
of UCB infusion to time of donor-derived hematopoietic recovery.
Each patient engrafted promptly, with days to donor-derived ab-
solute neutrophil count (ANC) 500/L being 13 and 29 days
respectively. No adverse events attributable to R-MetHuSCF in-
jections were observed. ’In vivo UCB expansion’ with administra-
tion of concomitant R-MetHuSCF and ﬁlgrastim may facilitate
prompt donor hematologic engraftment in adult UCB transplant
recipients.
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AN ALGORITHM FOR SELECTION OF STEM CELL PRODUCTS FOR
TRANSPLANTATION
Barker, J.N. Memorial Sloan-Kettering Cancer Center, New York, NY
To date no prospective randomized studies of unrelated volun-
teer donor bone marrow transplantation (BMT) versus umbilical
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